Trust Dvb T 16738 Code Keygen
Karmen Mcarthun
The National Cancer Patient Experience Survey aims to understand the experiences of cancer care across England. We have sent you this survey because we would like to understand about your experiences of the NHS cancer care you received. This will help us to improve patient experience of existing cancer care services.
All adult patients (aged 16 and over), with a primary diagnosis of cancer, who have been admitted to hospital as inpatients for cancer related treatment, or who were seen as day case patients for cancer related treatment and have been discharged between April and June each year are included in the survey.
Picker, an independent research agency, administers the survey for NHS England. NHS England leads the National Health Service (NHS) in England. You can find out more about NHS England on the NHS England website.
If you would prefer to give anonymous feedback, you could ask staff at the hospital for information about how to give feedback using the Friends and Family Test (FFT). The FFT is designed to be a quick and easy way to give anonymous feedback that will go directly to the staff providing your care.
Please answer as many of the questions as you can. The more questions you answer, the more we can understand what your experience was like. This will help us make improvements to cancer services in the future.
Yes, your progress saves automatically when completing the survey online. If you close your browser, your progress will be saved. When you are ready to continue with the survey, log in with your access code and continue where you left off.
Picker also provides a Freephone helpline where call advisors are available to complete the survey with you over the telephone (please refer to the letter that came with the questionnaire, for information).
Each person invited to take part in the survey is given a unique survey number and QR code so that your name and address are separated from your survey answers. This means that answers can be carefully recorded and that your answers are kept confidential.
Another way to complete the survey online is to use your access code. Each access code is 8 characters long and can be found on the first page of your letter with an online link. If you enter the link into your device, you will be asked to enter your access code so you can begin the survey.
You may have received the survey before. This is because we send questionnaires out to all people seen as inpatients or day case patients for cancer related treatment and who were discharged between April and June each year.
The survey results will also be used to understand how people experience cancer care and treatment when they have been diagnosed via Rapid Diagnostic Centres (RDCs). RDCs have been introduced into the NHS to get people diagnosed as early and as quickly as possible, for all patients with cancer symptoms or suspicious test results.
By participating in the survey, you give permission for us to send your survey response data to the National Disease Registration Service (NDRS), which is part of NHS England, where it will be included in the cancer registry.
Your personal details and some information about your cancer treatment have been used to identify you for this survey and will be used to analyse the results. These details were provided by the NHS trust that treated you. The details have been shared with Picker, who are carrying out the survey on behalf of NHS England.
Approval under Section 251 of the NHS Act 2006 is provided by the Confidentiality Advisory Group at the Health Research Agency ahead of any personal information being shared by NHS trusts with Picker. The Section 251 approval allows your details to be shared without your consent. The approval is granted following an independent review of the purposes and governance arrangements for the survey.
Your personal information will be handled securely, and the results published will not identify you. Each questionnaire has a unique number which is used by Picker to determine who has responded to the survey, and to send reminders to those who have not.
Philips is a company with strong market leadership positions, an extensive customer base, strong innovation portfolio, talented employees, and a global purpose-driven brand. Yet, as our 2022 performance underlines, we are not extracting the full value of our businesses and have disappointed many stakeholders.
My priority as CEO is to address operational challenges, improve performance, and drive progressive value creation through a strategy of focused organic growth and an innovation model shift to increase the impact of patient- and people-centric innovation at scale. Execution will be the key value driver, with three clear priorities around improving patient safety and quality, creating more reliable and resilient supply chains, and simplifying the way we work, so we are more agile and competitive.
In consultation with regulators around the world, we have also been conducting a comprehensive test and research program to better understand the potential health risks associated with the use of affected devices. I am very conscious that 18 months is long, but this work had to be done thoroughly. I am encouraged by the test results for the first-generation DreamStation devices, that account for over two thirds of the registered affected devices: the prevalence of visible foam degradation is low, and the emission of the detected volatile organic compounds and particulates are within the applicable safety limits and not expected to result in appreciable harm to health in patients.
We are fully committed to completing the Respironics recall and testing program in 2023. We will also implement all measures agreed with the US Food & Drug Administration (FDA) and US Department of Justice, including a consent decree, and rebuild ties with the FDA and other national regulators. We have put the leadership and end-to-end organization in place and have invested significantly in doing so. Across the company, we have assigned the highest priority to making the necessary step-up in patient safety and quality management and have elevated leadership of patient safety and quality to Executive Committee level.
The set of measures we have taken includes the very difficult, yet necessary decisions announced in October 2022 and January 2023 to reduce our workforce by 4,000 employees and then a further 6,000 respectively, as we drive a major step-up in productivity. We will strive to implement these reductions with due respect for every employee affected and in line with all local rules and regulations.
We believe that, together, these measures will help us establish the culture, capabilities and infrastructure needed to consistently execute and deliver as a reliable patient- and people-centric health technology company.
As well as restoring our reputation as a responsible patient- and people-centric innovation leader in health technology, we urgently need to get back on course to create value with sustainable impact. To do this, we will drive organic growth through scale and leadership:
We will leverage our distinctive market positions, especially our strong presence in North America and many international markets, while further localizing to support our leadership position in China.
Looking back on last year, sales increased nominally to EUR 17.8 billion, while several factors weighed down on profitability. Performance was impacted by our efforts to mitigate supply chain and inflationary pressures and the revenue and cost consequences of the Philips Respironics sleep recall, whilst at the same time dealing with global challenges such as the COVID situation in China, volatile demand and supply, and the war in Ukraine. As we worked through the operational challenges, we progressed on our execution priorities in the fourth quarter and saw initial signs of improvement.
We remain cautious in light of the subdued economic outlook for the year, staffing and inflationary pressures facing our customers, geopolitical risks, supply and demand volatility, and uncertainties around ongoing consent decree negotiations, litigation and Department of Justice investigations. Nevertheless, we expect that, by prioritizing patient safety and quality, tightening our focus on innovation and strengthening our category leadership areas, while at the same time improving execution and taking a disciplined approach to capital, we will be able to progressively create value with sustainable impact. Against this background, and reflecting the importance we attach to dividend stability, we propose to maintain the dividend at EUR 0.85 per share, to be distributed in shares.
I am honored to have been tasked with leading our company and am heartened by the support I have encountered from our employees and customers, investors and other stakeholders. I am realistic about the challenges we face, but have full confidence in our plan of action and am firm in my resolve to lead Philips back to a position of strength in a world that needs meaningful innovation.
Roy Jakobs joined Philips in 2010 and has held various global leadership positions across the company, starting as Chief Marketing & Strategy Officer for Philips Lighting. In 2012, he became Market Leader for Philips Middle East & Turkey, leading the Healthcare, Consumer, and Lighting businesses out of Dubai. Subsequently, he became Business Leader of Domestic Appliances, based in Shanghai, in 2015. In 2018, Roy joined the Executive Committee as Chief Business Leader of the Personal Health businesses and in early 2020 he started as Chief Business Leader of Connected Care. Prior to his career at Philips, he held various management positions at Royal Dutch Shell and Reed Elsevier.
This page reflects the composition of the Executive Committee as per December 31, 2022. As announced on December 8, 2022, Kees Wesdorp left the company on January 1, 2023, with Bert van Meurs (Chief Business Leader for the Image Guided Therapy businesses) temporarily expanding his role to include the leadership of the Precision Diagnosis businesses. As announced on January 30, 2023, Steve C. de Baca and Jeff DiLullo joined the Executive Committee, effective February 6, 2023, as Chief Patient Safety & Quality Officer and Chief Market Leader of Philips North America, respectively. As such, Mr DiLullo succeeds Vitor Rocha, who left the company effective as per the same date. Philips expects to announce new leaders for its Connected Care businesses (which was the responsibility of Roy Jakobs until his appointment as CEO) as well as for its Precision Diagnosis businesses, in 2023. For a current overview of the Executive Committee members, see also -w/about/executive-committee.html
b37509886e